Tradename: VYJUVEK
Proper Name: beremagene geperpavec-svdt
Indication: Indicated for treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Approval Date: 05/19/2023
Manufacturer: Krystal Biotech, Inc.
More: https://www.fda.gov/vaccines-blood-biologics/vyjuvek